RET Testing in Papillary and Medullary Thyroid Cancer
Key opinion leaders consider how often NGS testing should be done in patients with papillary and medullary thyroid cancer, and which fusions should be considered.
Related Articles
Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations
Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.
OncLive’s December Roundup of Key FDA Approvals in Oncology
Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.
Working on the Frontlines of a Revolution in Multiple Myeloma Care
A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly…
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care
Since it’s implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and…
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care
Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
Community Practice Training During Fellowship Often Falls Short
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The Diagnosis and Prevalence of Secondary AML
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.